ZAI LAB LIMITED Other Cost of Operating Revenue
ZAI LAB LIMITED (ZLAB) reported Other Cost of Operating Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OtherCostOfOperatingRevenue · last filed 2026-08-06
- ZAI LAB LIMITED other cost of operating revenue for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- ZAI LAB LIMITED other cost of operating revenue for the quarter ending 2026-03-31 was $20.00K, a 89.74% decline year-over-year.
- ZAI LAB LIMITED other cost of operating revenue for the quarter ending 2025-12-31 was $30.00K, a 90.29% decline year-over-year.
- ZAI LAB LIMITED other cost of operating revenue for the quarter ending 2025-09-30 was $119.00K, a 65.80% decline year-over-year.
- ZAI LAB LIMITED other cost of operating revenue for fiscal 2025 was $561.00K, a 24.39% decline from fiscal 2024.
- ZAI LAB LIMITED other cost of operating revenue for fiscal 2024 was $742.00K.
- ZAI LAB LIMITED other cost of operating revenue for fiscal 2023 was $0.00.
- ZAI LAB LIMITED other cost of operating revenue for fiscal 2022 was $0.00.
| Period end | Other Cost of Operating Revenue 3 month | Other Cost of Operating Revenue 6 month | Other Cost of Operating Revenue 9 month | Other Cost of Operating Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-06 | $20.00K 10-Q · filed 2026-08-06 | $50.00K derived: sum of 3 quarters · filed 2026-08-06 | $169.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $20.00K 10-Q · filed 2026-05-07 | $50.00K derived: sum of 2 quarters · filed 2026-05-07 | $169.00K derived: sum of 3 quarters · filed 2026-05-07 | $386.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $149.00K derived: sum of 2 quarters · filed 2026-02-26 | $366.00K derived: sum of 3 quarters · filed 2026-08-06 | $561.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $119.00K 10-Q · filed 2025-11-06 | $336.00K derived: sum of 2 quarters · filed 2026-08-06 | $531.00K 10-Q · filed 2025-11-06 | $840.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $217.00K 10-Q · filed 2026-08-06 | $412.00K 10-Q · filed 2026-08-06 | $721.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $195.00K 10-Q · filed 2026-05-07 | $504.00K derived: sum of 2 quarters · filed 2026-05-07 | $852.00K derived: sum of 3 quarters · filed 2026-05-07 | $937.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $309.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $657.00K derived: sum of 2 quarters · filed 2026-02-26 | $742.00K derived: sum of 3 quarters · filed 2026-02-26 | $742.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $348.00K 10-Q · filed 2025-11-06 | $433.00K derived: sum of 2 quarters · filed 2025-11-06 | $433.00K 10-Q · filed 2025-11-06 | $433.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $85.00K 10-Q · filed 2025-08-07 | $85.00K 10-Q · filed 2025-08-07 | $85.00K derived: sum of 3 quarters · filed 2026-02-26 | $85.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $0.00 10-Q · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |